Evidence mapPaperPMID 15197140Full record

Trial reportCirculation2004

Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus.

Katherine Esposito, Dario Giugliano, Francesco Nappo, Raffaele Marfella, Campanian Postprandial Hyperglycemia Study Group

2 registry-linked trialsOpen access · bronzeAbstract readClinical TrialComparative StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Circulation, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 129 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
129citing papers in PubMed, 10 pooled it
23.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01524705 phase4completedstarted 2012, after this paper: background citation

FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR

Ran2012Enrolled102Registered outcomes4Posted comparisons3ConditionsType 2 DiabetesArmsexenatide, Insulin glargine, Metformin, Prandial insulin
Open the trial in the graph
NCT03819790 phase4completedstarted 2018, after this paper: background citation

Variability of Glucose Assessed in a Randomized Trial Comparing the Initiation of A Treatment Approach With Biosimilar Basal Insulin Analog Or a Titratable iGlarLixi combinatioN in Type 2 Diabetes Among South Asian Subjects (VARIATION 2 SA Trial)

Ran2018Enrolled119Registered outcomes30Posted comparisons0ConditionsDiabetes Mellitus, Type 2ArmsBasal insulin Basaglar/Lantus + gliclazide MR, Basal insulin glargine and lixisenatide, Metformin
Open the trial in the graph
3 · Its place in the literature

Who cites it

129 citing papers in PubMed, 10 syntheses or guidelines pooled it, 444 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pharmacological interventions for asymptomatic carotid stenosis.The Cochrane database of systematic reviews · 2023 · on this map
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. International Diabetes Federation guideline for management of postmeal glucose: a review of recommendations.Diabetic medicine : a journal of the British Diabetic Association · 2008
    Guideline
  10. Diabetes: glycaemic control in type 2.BMJ clinical evidence · 2008
    Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Twenty Minute Moderate-Intensity Post-Dinner Exercise Reduces the Postprandial Glucose Response in Chinese Patients with Type 2 Diabetes.Medical science monitor : international medical journal of experimental and clinical research · 2018
    Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

69 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Katherine EspositoDepartment of Geriatrics and Metabolic Diseases, Policlinico Universitario, Piazza L. Miraglia, 80138 Naples, Italy. dario.giugliano@unina2.it
Dario Giugliano
Francesco Nappo
Raffaele Marfella
Campanian Postprandial Hyperglycemia Study Group
Ospedale D. Cotugno · ITEuropean School of Molecular Medicine · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPostprandial hyperglycemia may be a risk factor for cardiovascular disease. We compared the effects of two insulin secretagogues, repaglinide and glyburide, known to have different efficacy on postprandial hyperglycemia, on carotid intima-media thickness (CIMT) and markers of systemic vascular inflammation in type 2 diabetic patients. METHODS AND

resultsWe performed a randomized, single-blind trial on 175 drug-naive patients with type 2 diabetes mellitus (93 men and 82 women), 35 to 70 years of age, selected from a population of 401 patients who participated in an epidemiological analysis assessing the relation of postprandial hyperglycemia to surrogate measures of atherosclerosis. Eighty-eight patients were randomly assigned to receive repaglinide and 87 patients to glyburide, with a titration period of 6 to 8 weeks for optimization of drug dosage and a subsequent 12-month treatment period. The effects of repaglinide (1.5 to 12 mg/d) and glyburide (5 to 20 mg/d) on CIMT were compared by using blinded, serial assessments of the far wall. After 12 months, postprandial glucose peak was 148+/-28 mg/dL in the repaglinide group and 180+/-32 mg/dL in the glyburide group (P<0.01). HbA(1c) showed a similar decrease in both groups (-0.9%). CIMT regression, defined as a decrease of >0.020 mm, was observed in 52% of diabetics receiving repaglinide and in 18% of those receiving glyburide (P<0.01). Interleukin-6 (P=0.04) and C-reactive protein (P=0.02) decreased more in the repaglinide group than in the glyburide group. The reduction in CIMT was associated with changes in postprandial but not fasting hyperglycemia.

conclusionsReduction of postprandial hyperglycemia in type 2 diabetic patients is associated with CIMT regression.

Indexed as

Postprandial PeriodAdultAgedBiomarkersBlood GlucoseCarbamatesCarotid Artery DiseasesCross-Sectional StudiesDiabetes Mellitus, Type 2FastingFemaleGlyburideGlycated HemoglobinHumansHyperglycemiaHypoglycemic AgentsBiomarkersBlood GlucoseCarbamatesGlyburideGlycated HemoglobinHypoglycemic AgentsInsulinLipidsPiperidinesrepaglinide

Identifiers

PMID15197140
OpenAlexW2042518766

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.